Virios Therapeutics, Inc. is a biotechnology firm in its development phase, dedicated to pioneering antiviral treatments for conditions that arise from an unusual immune response triggered by viral infections. Its primary investigational compound, IMC-1, is a precisely formulated blend of famciclovir and celecoxib, currently being developed to address fibromyalgia. Additionally, the company is advancing IMC-2, a therapeutic combination of valacyclovir and celecoxib, aimed at mitigating the various long COVID symptoms, including ongoing fatigue, sleep disturbances, cognitive challenges, pain, autonomic dysfunction, and anxiety.